Rite Aid and Elixir: The Rebate Settlement Behind the Service-Fee Label

Rite Aid and Elixir Insurance Company agreed to pay $101 million in a rebate settlement case to resolve allegations that they falsely reported manufacturer rebates as service fees to Medicare Part D. The government alleged that the manufacturers had never negotiated those fees. For someone inside rebate accounting, the question is concrete: what service was the money supposed to buy?

The Justice Department announced the settlement on July 10, 2024. A former Rx Options employee brought the whistleblower case, and the United States joined it. The Civil Division and the U.S. Attorney’s Office for the Northern District of Ohio handled the case, with substantial investigative assistance from HHS-OIG and the FBI’s Cleveland office.

The allegations covered January 1, 2014 through December 31, 2020. They concerned the path from manufacturer rebates through the PBMs to the sponsor’s Medicare reports. The money retained inside that arrangement, and the label attached to it, were the heart of the case.

Who Was the Sponsor and Who Were the PBMs?

Elixir Insurance Company was the plan sponsor, offering Medicare Part D prescription drug plans. Elixir Rx Options and Elixir Rx Solutions acted as pharmacy benefit managers, processing prescriptions, helping with drug utilization and negotiating manufacturer rebates. Rite Aid owned the pharmacy-services business known as Elixir.

The whistleblower’s complaint describes a division of work that matters to anyone tracing the money. Rx Options managed pharmacy-provider contracts and employed the Envision companies’ staff. Rx Solutions held the manufacturer trade contracts covering rebates and formularies.

According to the complaint, the affiliated insurer contracted with Rx Options, which subcontracted with Rx Solutions for manufacturer negotiations. Unaffiliated insurance-plan clients contracted with Rx Solutions, which used Rx Options for the pharmacy network. The corporate group could therefore hold both the manufacturer relationship and the sponsor’s reporting responsibility, through different companies. Rite Aid sold the other Elixir entities’ assets in 2024, but Elixir Insurance remained a party to the settlement.

How Manufacturer Rebates Reach Medicare’s Accounts

Medicare Part D sponsors report manufacturer rebates and other remuneration to the Centers for Medicare and Medicaid Services annually. The agency uses those reports to reconcile payments at the end of the year, determining what the government owes the plan or what the plan owes the government. The point is to give Medicare the benefit of price concessions that reduce covered drug costs.

Manufacturer rebates can arrive after a pharmacy has dispensed the prescription. They can reward inclusion on a plan’s formulary, its list of covered drugs. That leaves different records describing different stages of the same business: the prescription claim, the manufacturer’s rebate payment and the sponsor’s final accounting to Medicare.

Annual Direct and Indirect Remuneration reports capture price concessions that arrive after the point of sale. These annual rebate reports connect the manufacturer’s payment to Medicare’s final accounting for the drug.

The alleged misclassification also had a specific place on the form. The complaint explains that bona fide service fees still appeared on the annual DIR report, but in a separate section for amounts not treated as DIR. The complaint alleged that this classification let Rx Solutions keep the retained rebates as profit instead of passing the savings to Medicare. That would leave taxpayers without the benefit of the lower drug cost.

The Alleged Service Fees Had No Negotiated Service

The government alleged that the defendants retained manufacturer rebates without the manufacturers’ knowledge and reported them as bona fide service fees. It also alleged that Elixir Insurance knew the retained amounts did not qualify for that treatment. The complaint supplies the business detail behind the government’s allegation: the retained amounts allegedly followed the rebates, rather than the quantity or value of services performed.

The whistleblower put the missing service plainly, referring to Rx Solutions by its former abbreviation, EPS:

The complaint describes manufacturer services such as rebate administration and data collection. It explains that genuine service fees pay for work, rather than reduce the drug’s price. Its account of the service-fee criteria requires actual, itemized work the manufacturer would otherwise perform or hire someone to do, fair-market-value compensation, and a fee not passed on to a client or customer. Those details make the manufacturer’s agreement and valuation important: what work did it buy, and what did it agree that work was worth?

Here, the whistleblower alleged that the manufacturer contracts did not provide for the retained amounts as service fees. The complaint also alleged that manufacturers had neither conducted nor supplied fair-market-value analyses supporting them. Instead, it alleged:

According to the complaint, those documents were intended to support the classification in an audit. That is a revealing allegation: paperwork created to defend the fee, while the manufacturer allegedly had not agreed to pay it.

The complaint placed this practice specifically in the affiliated insurer’s business. It alleged that Rx Solutions retained these rebates for Elixir Insurance’s Part D beneficiaries, although it served other insurance plans. It further alleged that Rite Aid’s chief executive and chief financial officer heard about the practice, expressed concern and allowed it to continue within the affiliated plan.

One annual report makes the scale concrete. The complaint alleged that Elixir Insurance reported approximately $65 million as service fees in its 2018 annual rebate reports, although the money consisted of manufacturer rebates retained by Rx Solutions. It alleged that Elixir Insurance’s president certified those reports as true and accurate. We see the imbalance: one year’s alleged retention against a $101 million payment obligation for years of alleged conduct.

The Retention Formula Changed Its Base

The agreement describes the government’s allegation as 20% of total estimated manufacturer rebates from 2014 through 2019, followed by 5.5% of the wholesale acquisition cost of rebateable drugs in 2020. Those percentages use different bases.

Wholesale acquisition cost is a manufacturer’s list price to wholesalers or direct purchasers before discounts and rebates. A percentage of that price measures something different from a percentage of the rebate.

What the Bankruptcy Settlement Required

The settlement agreement required Elixir Insurance and Rite Aid to make their payments in installments through 2028. It separately required Rx Options and Rx Solutions to grant the government a combined $20 million claim in the bankruptcy, divided equally between the PBMs. The agreement called the payments and bankruptcy claims together a $121 million total settlement amount. The Justice Department said the settlement reflected the companies’ ability to pay.

Does a Settlement Headline Determine a Reward?

No. A whistleblower’s reward is a share of the government’s recovery. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

What Rebate Accounting Can Reveal

The useful connection runs from the manufacturer’s agreement and actual remittance to the amount retained, its classification in the sponsor’s report, the certification and Medicare’s reconciliation. Someone who works on those healthcare accounts may know why the payment received one description internally and another in the federal submission.

The complaint’s alleged audit paperwork adds another dimension. In health care fraud, a report’s supporting file can be as revealing as its final number. Who supplied the valuation, what service it described and whether the manufacturer had agreed to that service all bear on the explanation the sponsor gave Medicare. We work with insiders to connect that knowledge to the payment and the decisions behind it.

A separate Caremark Part D reporting case shows another way later accounting can change the story. The court found that higher Part D pharmacy payments reduced Caremark’s commercial reconciliation obligations under pricing commitments spanning both books of business. It treated those offsets as price concessions that Medicare reporting had to reflect. Reconciliation workbooks helped show the connection.

Elixir’s settlement concerned alleged rebates relabeled as service fees. Caremark’s findings concerned offsets across different insurance business. In both, the reporting question required looking beyond the prescription’s initial payment to the financial arrangements that followed it.

Your View of the Rebate Accounts

If you know why a manufacturer rebate became a service fee in a Medicare report, speak with our whistleblower experts about how the rebate became a fee. We build your strongest PBM whistleblower case with you around the money, the reporting and the decisions, and bring in PBM fraud whistleblower lawyers who understand manufacturer rebates and Part D reconciliation. You have a partner from the first conversation through the pursuit of the recovery.